“Our collaboration with BDI is part of our strategy of leveraging cutting-edge technologies and academic research to deliver innovative, breakthrough solutions for our customers,“ said Dennis Harris, Millipore’s Chief Scientific Officer. “Our relationship with BDI gives us access to a comprehensive range of world-class diagnostic capabilities focused on resolving unmet bioanalytic needs.”

“This partnership with Millipore represents a wonderful opportunity for BDI to engage with an industry leader in the life science field,” said Professor Brian MacCraith, BDI Director. “Our collaboration will enable the application of our cutting-edge diagnostic technologies to improve production of novel therapeutics, which will impact health care and patients’ lives.”

Millipore’s current research with BDI is focused on developing new technology platforms for in-process testing and real-time monitoring in biopharmaceutical manufacturing.

“I’m very impressed with the breadth of BDI’s technologies and the depth of its expertise in point-of-care diagnostic solutions,” said Holger Schwarz, Director of Technology and Alliances in Millipore’s Corporate Technology Office and a newly elected member of BDI’s Executive Committee. “Being a full BDI industry member presents us with a unique opportunity to leverage technologies developed at BDI to solve problems for our customers in academia and industry—in the areas of life science research, drug discovery, diagnostics and biomanufacturing.”

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER^®
Research. Development. Production.

About BDI

The Biomedical Diagnostics Institute (BDI), based at Dublin City University, Dublin, Ireland, is a multi-disciplinary consortium of academic, clinical and industrial partners focused primarily on the development of next-generation, point-of-care biomedical diagnostic devices. Over the past five years, it has developed a cutting-edge research program involving leading researchers from academic institutions, companies and the clinical environment to form a complementary, integrated, cohesive partnership. BDI is a Center for Science, Engineering and Technology (CSET) funded by Science Foundation Ireland (SFI).

Millipore Forward Looking Statement

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug; delay, suspension or termination of a customer’s volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of customers’ therapeutics; limitations on cash flow available for operations and investment due to increased debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for animal-derived cell culture products; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; the inability to achieve anticipated cost benefits of our supply chain initiatives; risks relating to our concentration of principal manufacturing operations; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Millipore Media Contact:

Karen Marinella Hall
Director of Corporate Communications
Millipore Corporation
Office: 978-715-1567
Cell: 508-212-9476
karen_hall@millipore.com

Investors:

Joshua Young
Director, Investor Relations
(978) 715-1527
joshua_young@millipore.com